MK-2870, CAPECITABINE , CYCLOPHOSPHAMIDE , PACLITAXEL , DEXAMETHASONE , DOXORUBICIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, EPIRUBICIN , CARBOPLATIN
MK-2870-032
Phase 3 small_molecule active
Quick answer
MK-2870, CAPECITABINE , CYCLOPHOSPHAMIDE , PACLITAXEL , DEXAMETHASONE , DOXORUBICIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, EPIRUBICIN , CARBOPLATIN for Breast Cancer: triple negative breast cancer (TNBC) and hormone receptor (HR)-low positive/HER2 negative breast cancer is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Breast Cancer: triple negative breast cancer (TNBC) and hormone receptor (HR)-low positive/HER2 negative breast cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active